Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Research & Development (2020 - 2025)

Tango Therapeutics (TNGX) has 6 years of Research & Development data on record, last reported at $32.8 million in Q2 2025.

  • For Q2 2025, Research & Development fell 15.13% year-over-year to $32.8 million; the TTM value through Jun 2025 reached $136.4 million, up 0.92%, while the annual FY2025 figure was $132.2 million, 8.17% down from the prior year.
  • Research & Development reached $32.8 million in Q2 2025 per TNGX's latest filing, down from $36.4 million in the prior quarter.
  • Across five years, Research & Development topped out at $38.7 million in Q2 2024 and bottomed at $15.0 million in Q1 2021.
  • Average Research & Development over 5 years is $28.4 million, with a median of $28.7 million recorded in 2022.
  • Peak YoY movement for Research & Development: surged 62.2% in 2022, then decreased 15.13% in 2025.
  • A 5-year view of Research & Development shows it stood at $21.6 million in 2021, then surged by 34.47% to $29.1 million in 2022, then increased by 7.73% to $31.3 million in 2023, then grew by 8.29% to $33.9 million in 2024, then dropped by 3.33% to $32.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $32.8 million in Q2 2025, $36.4 million in Q1 2025, and $33.9 million in Q4 2024.